A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

Allowed: BRCA1 pathogenic mutation

Allowed: BRCA2 pathogenic mutation

Must have received: second-generation androgen receptor-targeted therapy (abiraterone, enzalutamide, apalutamide, darolutamide)

Prior therapy with a second-generation androgen receptor (AR)-targeted therapy (e.g., abiraterone, enzalutamide, apalutamide, darolutamide)

Must have received: taxane

Prior therapy with a taxane regimen or are considered ineligible for treatment with a taxane regimen or have refused treatment with a taxane regimen

Must have received: PARP inhibitor

For participants with a known pathogenic BRCA1 or BRCA2 mutation: prior therapy with a poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor, or are considered ineligible for treatment with a PARP inhibitor, if such therapy is approved and available

Cannot have received: AR protein degrader

Treatment with any previous AR protein degrader